Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis

Fumihiro TakahashiMitsubishi Tanabe Pharma Corporation, Tokyo, Japan, and

Koji TakeiMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USACorrespondence[email protected]

Kikumi TsudaMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA

Joseph PalumboMitsubishi Tanabe Pharma Corporation, Tokyo, Japan, and ;Mitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA

References

Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–7.
PubMed Web of Science ®Google Scholar
The Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Suppl). Epub ahead of print. doi. 10.1080/21678421.2017.1363780.
Web of Science ®Google Scholar
The Writing Group for The Edaravone (MCI-186) ALS 17 Study Group. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017 (Suppl). Epub ahead of print. doi:10.1080/21678421.2017.1362000
Google Scholar
Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963–74.
PubMed Web of Science ®Google Scholar